Summary - ABVX - NASDAQ - Weiss Ratings

D

ABIVAX Société Anonyme ABVX

$86.51 -$0.50-0.58% NASDAQ

Recommendation

Prev Close

Volume

Avg Vol (90D)

Market Cap

Dividend & Yield

--

52-Week Range

$4.77 - $92.91

P/E (TTM)

--

EPS (TTM)

My Lists My Alerts

Access our Premium Ratings

Get Access

Rating

Reward

Risk

Rating Factors

Growth Index

Efficiency Index

Solvency Index

Total Return Index

Volatility Index

Dividend Index

Headlines

Weiss Ratings Reaffirms "Sell (D-)" Rating for Abivax (NASDAQ:ABVX)

10/8/2025 - MarketBeat

Abivax SA Sponsored ADR (ABVX) Receives a Rating Update from a Top Analyst

10/8/2025 - TipRanks Financial Blog

Abivax (NASDAQ:ABVX) Sees Large Volume Increase - Still a Buy?

10/6/2025 - MarketBeat

Abivax price target raised to $120 from $112 at BTIG

10/6/2025 - TipRanks Financial Blog

Abivax price target raised by $8 at BTIG, here's why

10/6/2025 - The Fly

Best Biotech Stocks To Follow Now - October 6th

10/6/2025 - MarketBeat

10/6/2025 - SeekingAlpha

10/6/2025 - Seeking Alpha: Transcripts

Spotlight on Abivax: Analyzing the Surge in Options Activity

10/6/2025 - Benzinga

Why Is Abivax Stock Trading Higher On Monday?

10/6/2025 - Benzinga

Top 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched Disease

10/6/2025 - Investor's Business Daily

Futures Jump On Latest Burst Of AI Euphoria Amid Global Political Turmoil

10/6/2025 - Zero Hedge

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in ...

10/6/2025 - GuruFocus

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

10/6/2025 - Globe Newswire

Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Recommendation of "Moderate Buy" from Analysts

10/6/2025 - MarketBeat

Abivax Reports Positive 8-Week Results From Phase 3 Trials Of Obefazimod In Ulcerative Colitis

10/6/2025 - Nasdaq News: Markets

Abivax (ABVX) Achieves Positive Outcomes in Phase 3 Ulcerative Colitis Trials

10/5/2025 - GuruFocus

Abivax announces ABTECT 1, ABTECT 2 trials met primary endpoint

10/5/2025 - TipRanks Financial Blog

Abivax announces ABTECT 1, ABTECT 2 trials met primary endpoint

10/5/2025 - The Fly

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

10/5/2025 - GuruFocus

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

10/5/2025 - Globe Newswire

FY2025 EPS Estimates for Abivax Raised by Lifesci Capital

10/2/2025 - MarketBeat

Citizens JMP Raises PT on ABIVAX Soci t Anonyme (ABVX) Stock

10/1/2025 - Insider Monkey

10 Unstoppable Stocks to Buy and Hold for the Next 5 Years

9/30/2025 - Insider Monkey

ABIVAX Soci t Anonyme (ABVX) to Present Phase 3 UC Data at UEG Congress, Investor Call Scheduled

9/30/2025 - Yahoo! Finance: News

Income Statement

Total Revenue (TTM)

EBITDA (TTM)

EBIT (TTM)

Net Income (TTM)

Balance Sheet

Total Assets (Q)

Total Debt (Q)

Total Liabilities (Q)

Book Value Per Share (Q)

Cash Flow

Cash from Operations (TTM)

Cash from Investing (TTM)

Cash from Financing (TTM)

Net Change in Cash (TTM)

Filings

Filing Date

Monday, September 8, 2025

Period Date

Monday, June 30, 2025

Next Filing

Week of Mar 23 and 27 (est)

Price History

Loading...

Beta

--

7-Day Total Return

30-Day Total Return

60-Day Total Return

90-Day Total Return

Year to Date Total Return

1-Year Total Return

2-Year Total Return

--

3-Year Total Return

--

5-Year Total Return

--

52-week Low

Apr 09, 2025 - $4.77

52-week High

Sep 05, 2025 - $92.91

Valuation

Market Cap

$6.54B - Mid Cap

Enterprise Value

Price/Sales (TTM)

Price/Book (Q)

Dividends and Shares

Shares Outstanding

Dividend Per Share (Most Recent)

--

Dividend Per Share (TTM)

--

Corporate Info

Website

Phone Number

33 1 53 83 09 63

Address

7-11 boulevard Haussmann
Paris, 75009

Country

Year Founded

Business Description

Sector

--

Industry

--

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in... more